Intraprocedural blood volume measurement using C-arm CT as a predictor for treatment response of malignant liver tumours undergoing repetitive transarterial chemoembolization (TACE).

PURPOSE: To evaluate feasibility of measuring parenchymal blood volume (PBV) of malignant hepatic tumours using C-arm CT, test the changes in PBV following repeated transarterial chemoembolization (TACE) and correlate these changes with the change in tumour size in MRI. METHODS: 111 patients with liver malignancy were included. Patients underwent MRI and TACE in a 4- to 6-week interval. During intervention C-arm CT was performed. Images were post-processed to generate PBV maps. Blood volume data in C-arm CT and change in size in MRI were evaluated. The correlation between PBV and size was tested using Spearman rank test. RESULTS: Pre-interventional PBV maps showed a mean blood volume of 84.5 ml/1000 ml ± 62.0, follow-up PBV maps after multiple TACE demonstrated 61.1 ml/1000 ml ± 57.5. The change in PBV was statistically significant (p = 0.02). Patients with initial tumour blood volume >100 ml/1000 ml dropped 7.1% in size and 47.2% in blood volume; 50-100 ml/1000 ml dropped 4.6% in size and 25.7% in blood volume; and <50 ml/1000 ml decreased 2.8% in size and increased 82.2% in blood volume. CONCLUSION: PBV measurement of malignant liver tumours using C-arm CT is feasible. Following TACE PBV decreased significantly. Patients with low initial PBV show low local response rates and further increase in blood volume, whereas high initial tumour PBV showed better response to TACE. KEY POINTS: Parenchymal blood volume assessment of malignant hepatic lesions using C-arm CT is feasible. The parenchymal blood volume is reduced significantly following transarterial chemoembolization. Parenchymal blood volume can monitor the response of tumours after transarterial chemoembolization. Although not significant, high initial parenchymal blood volume yields better response to TACE.

CT chest and gantry rotation time: does the rotation time influence image quality?

BACKGROUND: Computed tomography (CT) gantry rotation time is one factor influencing image quality. Until now, there has been no report investigating the influence of gantry rotation time on chest CT image quality. PURPOSE: To investigate the influence of faster gantry rotation time on image quality and subjective and objective image parameters in chest CT imaging. MATERIAL AND METHODS: Chest CT scans from 160 patients were examined in this study. All scans were performed using a single-source mode (collimation, 128 × 0.6 mm; pitch, 1.2) on a dual-source CT scanner. Only gantry rotation time was modified, while other CT parameters were kept stable for each scan (120 kV/110 reference mAs). Patients were divided into four groups based on rotation time: group 1, 1 s/ rotation (rot); group 2, 0.5 s/rot; group 3, 0.33 s/rot; group 4, 0.28 s/rot. Two blinded radiologists subjectively compared CT image quality, noise, and artifacts, as well as radiation exposure, from all groups. For objective comparison, all image datasets were analyzed by a radiologist with 5 years of experience concerning objective measurements as well as signal-to-noise ratio (SNR). RESULTS: We found that faster gantry rotation times (0.28 s/rot and 0.33 s/rot) resulted in more streak artifacts, image noise, and decreased image quality. However, there was no significant difference in radiation exposure between faster and slower rotation times (P > 0.7). CONCLUSION: Faster CT gantry rotation reduces scan time and motion artifacts. However, accelerating rotation time increases image noise and streak artifacts. Therefore, a slower CT gantry rotation speed is still recommended for higher image quality in some cases.

Image-guided microwave thermoablation of hepatic tumours using novel robotic guidance: an early experience.

OBJECTIVE: To evaluate and compare novel robotic guidance and manual approaches based on procedural accuracy, procedural time, procedural performance, image quality as well as patient dose during image-guided microwave thermoablation. METHOD: The study was prospectively performed between June 2013 and December 2013 using 70 patients. Forty randomly selected patients (group 1) were treated with manual guidance and 30 patients (group 2) were treated using a novel robotic guidance. Parameters evaluated were procedural accuracy, total procedural time, procedural performance, quantitative/qualitative image quality and patient dose. Two-sided Student's t test and Wilcoxon rank-sum test were used to test the significance of the data and p values less than 0.05 were considered statistically significant. RESULT: Accuracy parameters were significantly higher in group 2 (all p < 0.05). Total procedural time showed a mean time difference of 3 min (group 2 > group 1; p = 0.0008). Volume CT dose index and dose-length product were significantly lower for group 2 compared to group 1 (all p < 0.05) for CT fluoroscopy imaging. Total procedural performance score was higher for group 2 compared to group 1 (p = 0.0001). Image quality parameters were insignificant between examined groups. CONCLUSION: The novel robotic guided approach improved the accuracy of targeting the target tumour, reduced patient dose and increased procedural performance (which influences the procedural safety) during ablation. KEY POINTS: • Few reports are available in the literature regarding robotic-assisted liver microwave ablation. • The robotic guided approach improved accuracy of localizing the target tumour. • Radiation dose on patients was reduced with the robotic guidance. • Numbers of insertions and readjustments were reduced, lowering chances of complications.

Ultrafast cone-beam computed tomography imaging and postprocessing data during image-guided therapeutic practice.

OBJECTIVE: Our objective was to evaluate ultrafast cone-beam computed tomography (u-CBCT) image data using cross-sectional images, perfusion blood volume (PBV), and image fusion during tumour detection at the course of transarterial chemoembolization. METHODS: One hundred and fifty patients (63 ± 20 years; 33-82) were examined from February to October 2013 with u-CBCT. Tumour delineation and conspicuity were determined using u-CBCT cross-sectional PBV and u-CBCT-magnetic resonance imaging (MRI) fused data sets for hyperenhanced (HYET), heterogeneously enhanced (HEET), and unenhanced (UET) tumour categories. Catheter localisation and tumour feeding vessels were assessed using all data sets. Quantitative and qualitative analyses were performed using appropriate statistical tests. RESULT: Qualitative and quantitative tumour delineation showed significant difference (all P < 0.05) among tumour categories. Mean tumour-liver-contrast was higher in HYET than in HEET, and UET; moreover, differences between tumour categories were statistically significant (all P < 0.0001). Fused data showed higher value with statistical significance (P < 0.05) compared with other data sets during catheter localisation and feeding-vessel identification. CONCLUSION: Tumour delineation was clearly possible using u-CBCT cross sections with contrast material. PBV uses color-coded images to increase detection and produces good tumour differentiation. Image fusion helps accurately identify tumour and feeding vessels and locate contrast material injection sites and catheter tips without additional data acquisition. KEY POINTS: • Ultrafast CBCT cross-sectional data provide good tumour delineation with contrast material • Postprocessed PBV using u-CBCT increased detectability and tumour differentiation • u-CBCT cross-sectional PBV and u-CBCT-MRI data helps image guidance during chemoembolization • u-CBCT-MRI can identify tumours and feeding vessels and locate catheter tip accurately.

Oncological applications of dual-energy computed tomography imaging.

Dual-energy computed tomography (DECT) imaging is a promising method used in oncology for accurate detection/diagnosis of malignant and benign lesions. Use of dual-energy spectral, weighted average, color-coded map, and virtual unenhanced images provides increased visual detection and easy lesion delineation. Lesion detectability, sensitivity, and conspicuity are significantly improved using DECT. Material characterization and decomposition are promising using DECT. Both anatomical and functional information related to oncology can be provided by DECT using single contrast-enhanced CT.

Thermal ablation of liver metastases from colorectal cancer: radiofrequency, microwave and laser ablation therapies.

Surgery is currently considered the treatment of choice for patients with colorectal cancer liver metastases (CRLM) when resectable. The majority of these patients can also benefit from systemic chemotherapy. Recently, local or regional therapies such as thermal ablations have been used with acceptable outcomes. We searched the medical literature to identify studies and reviews relevant to radiofrequency (RF) ablation, microwave (MW) ablation and laser-induced thermotherapy (LITT) in terms of local progression, survival indexes and major complications in patients with CRLM. Reviewed literature showed a local progression rate between 2.8 and 29.7 % of RF-ablated liver lesions at 12-49 months follow-up, 2.7-12.5 % of MW ablated lesions at 5-19 months follow-up and 5.2 % of lesions treated with LITT at 6-month follow-up. Major complications were observed in 4-33 % of patients treated with RF ablation, 0-19 % of patients treated with MW ablation and 0.1-3.5 % of lesions treated with LITT. Although not significantly different, the mean of 1-, 3- and 5-year survival rates for RF-, MW- and laser ablated lesions was (92.6, 44.7, 31.1 %), (79, 38.6, 21 %) and (94.2, 61.5, 29.2 %), respectively. The median survival in these methods was 33.2, 29.5 and 33.7 months, respectively. Thermal ablation may be an appropriate alternative in patients with CRLM who have inoperable liver lesions or have operable lesions as an adjunct to resection. However, further competitive evaluation should clarify the efficacy and priority of these therapies in patients with colorectal cancer liver metastases.

Chest-abdomen-pelvis CT for staging in cancer patients: dose effectiveness and image quality using automated attenuation-based tube potential selection.

BACKGROUND: Evaluation of automated attenuation-based tube potential selection and its impact on image quality and radiation dose in CT (computed tomography) examinations for cancer staging. METHODS: A total of 110 (59 men, 51 women) patients underwent chest-abdomen-pelvis CT examinations; 55 using a fixed tube potential of 120 kV/current of 210 Reference mAs (using CareDose4D), and 55 using automated attenuation-based tube potential selection (CAREkV) also using a current of 210 Reference mAs. RESULTS: Diagnostic image quality was obtained from all patients. The median DLP (703.5 mGy · cm, range 390-2203 mGy · cm) was 7.9% lower when using the algorithm compared with the standard 120 kV protocol (median 756 mGy · cm, range 345-2267 mGy · cm). A reduction in potential to 100 kV occurred in 32 cases; therefore, these patients received significantly lower radiation exposure compared with the 120 kV protocol. CONCLUSION: Automated attenuation-based tube potential selection produces good diagnostic image quality in chest-abdomen-pelvis CT and reduces the patient's overall radiation dose by 7.9% compared to the standard 120 kV protocol.

Cone-beam computed tomography imaging: therapeutic staff dose during chemoembolisation procedure.

Cone-beam computed tomography (CBCT) imaging is an important requirement to perform real-time therapeutic image-guided procedures on patients. The purpose of this study is to estimate the personal-doseequivalent and annual-personal-dose from CBCT imaging during transarterial chemoembolisation (TACE). Therapeutic staff doses (therapeutic and assistant physician) were collected during 200 patient (65 ± 15 years, range: 40­86) CBCT examinations over six months. Absorbed doses were assessed using thermo-luminescent dosimeters during patient hepatic TACE therapy. We estimated personal-dose-equivalent (PDE) and annual-personal-dose (APD) from absorbed dose based oninternational atomic energy agency protocol. APD for therapeutic procedure was calculated (therapeutic physician: 5.6 mSv; assistant physician: 5.08 mSv) based on institutional work load. Regarding PDE, the hands of the staff members received a greater dose compared to other anatomical locations (therapeutic physician: 56 mSv, 72 mSv; assistant physician: 12 mSv, 14 mSv). Annual radiation doses to the eyes and hands of the staff members were lower compared to the prescribed limits by the International Commission on Radiological Protection (ICRP). PDE and APD of both therapeutic staff members were within the recommended ICRP-103 annual limit. Dose to the assistant physician waslower than the dose to the therapeutic physician during imaging. Annual radiation doses to eye-lenses and hands of both staff members were lower than prescribed limits.

Radiation dose to procedural personnel and patients from an X-ray volume imaging system.

OBJECTIVE: To evaluate the radiation dose received by procedural personnel and patients from an X-ray volume imaging (XVI) system during interventional procedures. METHODS: Forty patients were examined using catheter angiography (group A), digital subtraction angiography (group B) and cone-beam CT (CBCT, group C). Doses to procedural personnel (using thermo-luminescent dosimeters, TLDs) and patients were estimated. Image quality and lesion delineation were assessed using objective and subjective methods. Shapiro-Wilk, two-sided Student's t and Wilcoxon matched-pairs tests were used to test statistical significance. RESULTS: Doses (milligrays) measured in the hands and left knee of the interventionist were higher than those in an assistant physician (P < 0.05). Doses (dose-area product and skin entry dose) were lower in group A and higher in C compared with other groups; moreover, comparison among the groups were significant (all P = 0.0001). Subjective and objective lesion delineation showed significant results (all P < 0.05) among the tumour types considered. Image quality estimation showed the opposite results for objective and subjective analysis. CONCLUSION: More doses were obtained for hands of the procedural personnel compared to other anatomical regions measured. Catheter angiography showed lower dose compared with other imaging groups examined. Lesion delineation was clearly possible using CBCT. Objective and subjective analysis showed the opposite results regarding image quality because of higher noise levels and artefacts.

Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites.

AIM: To evaluate tumor response in patients with hypovascular liver metastases from the most common primary sites treated with chemoembolization. MATERIALS & METHODS: Chemoembolization was performed in 190 patients (five groups) who had hypovascular liver metastases from the colon (n = 66), breast (n = 40), uveal malignant melanoma (n = 20), pancreas (n = 48) and stomach (n = 16). Surgical resection of primary sites had been performed for all included patients. Tumor response, survival statistics from the first chemoembolization using Kaplan-Meier method and progression rate of embolized lesions were evaluated by analysis of variance with Tukey's post hoc test. RESULTS: Multiple comparison between the groups showed no statistical significant difference in local tumor response (H: 9.23; p > 0.05). Survival indices of the patients, including survival rate, progression-free survival rate, median survival time and time to progression, demonstrated significant difference between the groups during the follow-up period (H: 9.7; p = 0.045). The progression rate of treated liver metastases from colon, breast, uvea, pancreas and stomach were 16.6, 17.5, 30.0, 25.0 and 32.0%, respectively (p = 0.002). CONCLUSION: Hypovascular liver metastases treated with chemoembolization may demonstrate equal local response, but are significantly different in rate of progression and survival.

Dual-source 128-slice MDCT neck: radiation dose and image quality estimation of three different protocols.

PURPOSE: To estimate the radiation dose and image quality of single-source (SSCT), high-pitch (HPCT), and dual-energy (DECT) protocols of a dual-source CT (DSCT) system for the examination of neck. MATERIALS AND METHODS: 180 patients were randomized to one of the three protocols: 60 patients (age: 55.4 ± 12 years; range: 44-84 years) were examined with a SSCT, other 60 (59.5 ± 16.4 years; R: 40-85) with HPCT, and the last 60 (61.1 ± 14.9 years; R: 47-84) were examined with a DECT protocol. All examinations were performed using a DSCT system. The used protocols: Group-1 (SSCT: 120 kV; effective mAs: 185.4 ± 17.7), Group-2 (HPCT: 120 kV; eff. mAs: 97.7 ± 11.8), and Group-3 (DECT: 80 kV/140 kV with tin-filter; eff. mAs: 248.5 ± 25.7; 187 ± 21.2). A 100ml iomeprol non-ionic contrast material was injected in to the patients during examination. RESULTS: Insignificant results were yielded regarding SNR and CNR between the groups (group-1 vs. 2: 0.3125, group-1 vs. 0.6 W: 0.6875, group-2 vs. 0.6 W: 0.3125), except DECT-80 (group-1 vs. 80 kV: 0.04289, group-2 vs. 80 kV: 0.025, group-0.6 W vs.80 kV: 0.04567) and 140 kV data, moreover, qualitative analysis yielded the same results. Mean effective-dose was significantly lower (p<0.05) in group-2 (1.06 ± 0.16 mSv) compared to group-1 (2.05 ± 0.22 mSv) or group-3 (1.76 ± 0.2 mSv). Single- and dual-energy comparison showed a significant difference (group-1 vs. 3: p=0.00001 and group-2 vs. 3: p=0.00001) for CTDIvol (percent difference: 16%, 64%) or DLP (PD: 15.5%, 50.5%). CONCLUSION: Quantitative and qualitative analysis showed similar results for SSCT, HPCT, and DECT-0.6 W datasets regarding quality. HPCT yielded lower dose compared to other groups, however, the DECT achieved a lower and significant dose difference from the SSCT protocol. HPCT and DECT can be used with similar image quality and lower radiation dose compared to SSCT for the scans and can be utilized to various clinical advantages.

Nonselective transarterial chemoperfusion: a palliative treatment for malignant pleural mesothelioma.

PURPOSE: To evaluate tumor response by means of volumetric assessment, survival, and changes in patient symptoms after the treatment of unresectable and/or recurrent pleural mesothelioma by using regional nonselective transarterial chemoperfusion as a palliative treatment option. MATERIALS AND METHODS: This retrospective study was approved by the hospital ethical committee, and all patients signed an informed consent prior to treatment. Thirty-nine patients (mean age, 64.0 years; 10 women and 29 men) with unresectable pleural mesothelioma were treated with repetitive transarterial chemoperfusion between March 2007 and March 2010, with a mean of 2.9 sessions per patient at 4-week intervals. Transarterial chemoperfusion was performed by using mitomycin C, cisplatin, and gemcitabine. Computed tomography findings and patient symptoms were evaluated. Tumor response was evaluated by using Response Evaluation Criteria in Solid Tumors guidelines, and survival was assessed with the Kaplan-Meier method. The change in volume for the partial-response group was tested by using the Wilcoxon signed-rank test. RESULTS: In 36% of treated tumors (14 of 39), partial response was achieved, and tumor volume decreased from a mean value ± standard deviation of 839.6 mL ± 590.3 (range, 3.9-1972.2 mL) to 137 mL ± 399.8 (range, 0.88-1131.4; P = .00012). In 49% of tumors (19 of 39), stable disease was noted. In 15% of tumors (six of 39), progressive disease was seen. Mean specific growth rate of the tumor was 0.00158% per day. The mean survival time was 14.2 months (range, 2.1-33.1 months) from the start of treatment. For patients with tumors that responded to treatment, mean survival time was 15 months (range, 4.5-33.1 months). Mean time to disease progression was 2.6 months for all tumors, 1.5 months for stable disease, and 1.3 months for progressive disease. CONCLUSION: Transarterial chemoperfusion may have the potential to yield positive results and response in the treatment of recurrent and/or unresectable pleural mesothelioma. © RSNA, 2012.

Radiation dose and image quality of X-ray volume imaging systems: cone-beam computed tomography, digital subtraction angiography and digital fluoroscopy.

OBJECTIVE: Radiation dose and image quality estimation of three X-ray volume imaging (XVI) systems. METHODS: A total of 126 patients were examined using three XVI systems (groups 1-3) and their data were retrospectively analysed from 2007 to 2012. Each group consisted of 42 patients and each patient was examined using cone-beam computed tomography (CBCT), digital subtraction angiography (DSA) and digital fluoroscopy (DF). Dose parameters such as dose-area product (DAP), skin entry dose (SED) and image quality parameters such as Hounsfield unit (HU), noise, signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were estimated and compared using appropriate statistical tests. RESULTS: Mean DAP and SED were lower in recent XVI than its previous counterparts in CBCT, DSA and DF. HU of all measured locations was non-significant between the groups except the hepatic artery. Noise showed significant difference among groups (P < 0.05). Regarding CNR and SNR, the recent XVI showed a higher and significant difference compared to its previous versions. Qualitatively, CBCT showed significance between versions unlike the DSA and DF which showed non-significance. CONCLUSION: A reduction of radiation dose was obtained for the recent-generation XVI system in CBCT, DSA and DF. Image noise was significantly lower; SNR and CNR were higher than in previous versions. The technological advancements and the reduction in the number of frames led to a significant dose reduction and improved image quality with the recent-generation XVI system. KEY POINTS: • X-ray volume imaging (XVI) systems are increasingly used for interventional radiological procedures. • More modern XVI systems use lower radiation doses compared with earlier counterparts. • Furthermore more modern XVI systems provide higher image quality. • Technological advances reduce radiation dose and improve image quality.

Liver metastases of pancreatic cancer: role of repetitive transarterial chemoembolization (TACE) on tumor response and survival.

OBJECTIVE: To evaluate the effect of chemoembolization on pancreatic cancer liver metastases. METHOD: Thirty-two patients with pancreatic cancer liver metastases retrospectively underwent chemoembolization (4- to 8-week intervals). Size-based evaluation (response evaluation criteria in solid tumors [RECIST]) and survival indexes were assessed overall and for sex and number of lesions. RESULTS: Of the patients, 71.87% showed stable disease, 9.37% partial response (PR) and 18.75% progressive disease (PD). Survival rate for 1, 3, and 5 years from first TACE was 60%, 25%, and 11%, respectively. Median survival time was 16 months and for stable disease group was 20 months. Progression-free survival for 6 months and 1, 3, and 5 years was 84%, 57.3%, 20%, and 10%, respectively. There was significant difference between men and women in response. Survival rates for 1 and 5 years for the men were 80% and 14% and for the women were 47% and 0%. There was no significant difference between oligonodular liver lesion (n < 5) and multinodular (n > 5) groups. Survival rates for 1 and 5 years for oligonodular were 84% and 14%, and for multinodular was 50% and 0%. CONCLUSION: Repetitive TACE resulted in a relevant response for the control of liver metastases of pancreatic cancer with respectable median survival time. Interestingly, the number of lesions, statistically, was not an effective factor.

Leiomyoma volume changes at follow-up after uterine artery embolization: correlation with the initial leiomyoma volume and location.

PURPOSE: To study the changes in uterine leiomyoma volume after uterine artery embolization (UAE) and to correlate these changes with the initial tumor volume and location within the uterus. MATERIALS AND METHODS: The study was performed retrospectively on 28 consecutive patients (age, 37-57 years; mean, 48 y +/- 4.81) with 84 uterine leiomyomas. UAE was performed between June 2006 and August 2007. All tumors in all patients were evaluated. Magnetic resonance imaging was performed before UAE and 3 months and 1 year after UAE. The volume and location of each tumor were evaluated in consensus by two radiologists. RESULTS: The mean pre-UAE volume of the leiomyomas was 51.6 cm(3) (range, 0.72-371.1 cm(3); SD, 79.3). Seven tumors were submucous, 28 intramural, and 49 subserous. At 3-month follow-up, 83 tumors (98.8%) showed volume reduction (mean, 52.62% +/- 21.85%; range, 12.79%-96.67%) and one (1.2%) increased in volume. At 1-year follow-up, five tumors (6%) were undetectable, 72 (85.7%) showed a further volume reduction of 20.5% +/- 11.92% (range, 2.52%-58.72%) relative to the 3-month volume, and seven (8.3%) increased in volume. A statistically significant difference (P = .026 at 3 months and P = .0046 at 1 year) in percentage of volume change was observed based on tumor location; submucous tumors showed the greatest volume reduction and subserous tumors the least reduction. The initial tumor volume showed a weak negative correlation (Spearman correlation coefficients, -0.35 at 3 months and -0.36 at 1 year) with tumor volume change. CONCLUSIONS: UAE results in leiomyoma volume reduction at 3-month and 1-year follow-up. The tumor location plays an important role in volume changes and the initial tumor volume plays a minor role. Further studies with larger numbers of submucous leiomyomas are needed.